167 related articles for article (PubMed ID: 2680065)
1. Detection of transforming ras proteins containing leucine at position 61 by a new mouse monoclonal antibody, ras(53-69)Leu61.
Bizub D; Fischberg-Bender E; Heimer EP; Felix A; Skalka AM
Cancer Res; 1989 Nov; 49(22):6425-31. PubMed ID: 2680065
[TBL] [Abstract][Full Text] [Related]
2. Correlation between H-ras p21TLeu61 protein content and tumorigenicity of NIH3T3 cells.
Bizub D; Blair D; Alvord G; Skalka AM
Oncogene; 1988 Oct; 3(4):443-8. PubMed ID: 3078952
[TBL] [Abstract][Full Text] [Related]
3. Characterization of monoclonal antibodies specific to the activated ras p21 with aspartic acid at position 13.
La Vecchio JA; Hamer PJ; Ng SC; Trimpe KL; Carney WP
Oncogene; 1990 Aug; 5(8):1173-8. PubMed ID: 2202949
[TBL] [Abstract][Full Text] [Related]
4. Comparative immunohistochemical reactivity of monoclonal and polyclonal antibodies to H-ras p21 in normal and neoplastic tissues of rodents and humans.
Ward JM; Perantoni AO; Santos E
Oncogene; 1989 Feb; 4(2):203-13. PubMed ID: 2648257
[TBL] [Abstract][Full Text] [Related]
5. T cell recognition of transforming proteins encoded by mutated ras proto-oncogenes.
Peace DJ; Chen W; Nelson H; Cheever MA
J Immunol; 1991 Mar; 146(6):2059-65. PubMed ID: 2005390
[TBL] [Abstract][Full Text] [Related]
6. Characterization of monoclonal antibody R256, specific for activated ras p21 with arginine at 12, and analysis of breast carcinoma of v-Harvey-ras transgenic mouse.
Pullano TG; Sinn E; Carney WP
Oncogene; 1989 Aug; 4(8):1003-8. PubMed ID: 2474786
[TBL] [Abstract][Full Text] [Related]
7. Frequent activation of non-ras transforming sequences in neoplastic Syrian hamster cells initiated with chemical carcinogens.
Notario V; Castro R; Flessate DM; Doniger J; DiPaolo JA
Oncogene; 1990 Sep; 5(9):1425-30. PubMed ID: 2216466
[TBL] [Abstract][Full Text] [Related]
8. Presence and possible role of c-ras and nuclear (c-fos and c-jun) proto-oncogene products in preimplantation embryonic development in mice.
Ahmad K; Naz RK
Mol Reprod Dev; 1993 Nov; 36(3):297-306. PubMed ID: 8286110
[TBL] [Abstract][Full Text] [Related]
9. Activated Val-12 ras p21 in cell culture fluids and mouse plasma.
Hamer PJ; La Vecchio J; Ng S; DeLellis R; Wolfe H; Carney WP
Oncogene; 1991 Sep; 6(9):1609-15. PubMed ID: 1923528
[TBL] [Abstract][Full Text] [Related]
10. Preparation, characterization and properties of monoclonal antibodies against intact H-ras p21 proteins.
Sorrentino V; Nebreda AR; Alonso T; Santos E
Oncogene; 1989 Feb; 4(2):215-22. PubMed ID: 2467247
[TBL] [Abstract][Full Text] [Related]
11. Characterization of a transforming N-ras gene in the human hepatoma cell line Hep G2: additional evidence for the importance of c-myc and ras cooperation in hepatocarcinogenesis.
Richards CA; Short SA; Thorgeirsson SS; Huber BE
Cancer Res; 1990 Mar; 50(5):1521-7. PubMed ID: 2154325
[TBL] [Abstract][Full Text] [Related]
12. Intracellular expression of the monoclonal anti-ras antibody Y13-259 blocks the transforming activity of ras oncogenes.
Montano X; Jimenez A
Cell Growth Differ; 1995 May; 6(5):597-605. PubMed ID: 7647040
[TBL] [Abstract][Full Text] [Related]
13. trans-Dominant suppressor mutations of the H-ras oncogene.
Ogiso Y; Gutierrez L; Wrathall LS; Lu YY; Blair DG; Clanton DJ; Hwang YW; Shih TY
Cell Growth Differ; 1990 May; 1(5):217-24. PubMed ID: 2150753
[TBL] [Abstract][Full Text] [Related]
14. Expression of adaptor protein Ruk/CIN85 isoforms in cell lines of various tissue origins and human melanoma.
Mayevska O; Shuvayeva H; Igumentseva N; Havrylov S; Basaraba O; Bobak Y; Barska M; Volod'ko N; Baranska J; Buchman V; Drobot L
Exp Oncol; 2006 Dec; 28(4):275-81. PubMed ID: 17285110
[TBL] [Abstract][Full Text] [Related]
15. Identification of a serum-inducible messenger RNA (5B10) as the mouse homologue of calcyclin: tissue distribution and expression in metastatic, ras-transformed NIH 3T3 cells.
Guo XJ; Chambers AF; Parfett CL; Waterhouse P; Murphy LC; Reid RE; Craig AM; Edwards DR; Denhardt DT
Cell Growth Differ; 1990 Jul; 1(7):333-8. PubMed ID: 2177633
[TBL] [Abstract][Full Text] [Related]
16. A monoclonal antibody reactive with an activated ras protein expressing valine at position 12.
Carney WP; Hamer P; Petit D; Wolfe H; Cooper G; Lefebvre M; Rabin H
J Cell Biochem; 1986; 32(3):207-14. PubMed ID: 3536974
[TBL] [Abstract][Full Text] [Related]
17. The product of the cph oncogene is a truncated, nucleotide-binding protein that enhances cellular survival to stress.
Velasco JA; Avila MA; Notario V
Oncogene; 1999 Jan; 18(3):689-701. PubMed ID: 9989819
[TBL] [Abstract][Full Text] [Related]
18. Antisera to the variable region of ras oncogene proteins, and specific detection of H-ras expression in an experimental model of chemical carcinogenesis.
Bizub D; Heimer EP; Felix A; Chizzonite R; Wood A; Skalka AM; Slater D; Aldrich TH; Furth ME
Oncogene; 1987 May; 1(2):131-42. PubMed ID: 2449645
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of oncogene-mediated transformation by ectopic expression of p21Waf1 in NIH3T3 cells.
Michieli P; Li W; Lorenzi MV; Miki T; Zakut R; Givol D; Pierce JH
Oncogene; 1996 Feb; 12(4):775-84. PubMed ID: 8632899
[TBL] [Abstract][Full Text] [Related]
20. v-Ras and v-Raf block differentiation of transformable C3H10T1/2-derived preadipocytes at lower levels than required for neoplastic transformation.
Raptis L; Brownell HL; Lu Y; Preston T; Narsimhan RP; Anderson S; Schaefer E; Haliotis T
Exp Cell Res; 1997 Aug; 235(1):188-97. PubMed ID: 9281368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]